Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | WNT3 | P56703 | 2/20 | 0.46 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30020095 | 0.90 | UCHL1 (0.46) | HSD17B10UCHL1NPC1HRH2HRH1 | |
| SCHEMBL27154398 | 0.84 | — | — | |
| SCHEMBL27143853 | 0.83 | KDM4E (0.50) | MEN1KMT2A | |
| SCHEMBL5408443 | 0.78 | NPC1 (0.57) | HSD17B10UCHL1NPC1HRH2HRH1 | |
| SCHEMBL3530509 | 0.78 | NPC1 (0.57) | HSD17B10UCHL1NPC1HRH2HRH1 | |
| SCHEMBL24896686 | 0.78 | HSD17B10 (0.58) | HSD17B10UCHL1NPC1HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL30020380 | 0.76 | KDM4E (0.47) | MEN1KMT2A | |
| SCHEMBL27150678 | 0.76 | KDM4E (0.44) | MEN1KMT2A | |
| SCHEMBL1251121 | 0.75 | NPC1 (0.53) | HSD17B10UCHL1NPC1HRH2HRH1 | |
| SCHEMBL2136252 | 0.75 | NPC1 (0.53) | HSD17B10UCHL1NPC1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-4326724-A1 | COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2024-02-28 | — | — | EP | disclosed |
| CN-117120443-A | Compounds as adenosine A2a receptor antagonists and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022224180-A1 | COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | HSD17B10 2827/4885UCHL1 4251/4885NPC1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.